Clinical Trials on Artrosis of the Knee in Poland

Total 676 results

AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
Sanofi

Completed

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Alzheimer Disease

United States, Canada
Genentech, Inc.

Active, not recruiting

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

Multiple Sclerosis, Relapsing

United States, Puerto Rico, Kenya
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Germany, Austria, Belgium, France, Israel, Italy
Sanofi

Completed

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

Multiple Sclerosis

United States, Australia, Austria, Bulgaria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Russian Federation, Turkey, Ukraine, United Kingdom
Sesen Bio, Inc.

Terminated

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Squamous Cell Carcinoma of the Head and Neck | Neoplasms, Squamous Cell | Mouth Neoplasms

United States, Canada
Celgene

Completed

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Multiple Sclerosis

United States, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Republic of, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South... and more
Oregon Health and Science University
Jacobus Pharmaceutical

No longer available

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Lambert-Eaton Myasthenic Syndrome (LEMS) | Congenital Myasthenia (CM)

United States
Catalyst Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Lambert Eaton Myasthenic Syndrome

United States, Spain, Serbia, Russian Federation, Hungary, France, Germany, Poland
SK Life Science, Inc.

Enrolling by invitation

Cenobamate Open-Label Extension Study for YKP3089C025

Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy

United States, Bulgaria, Czechia, Hungary, Poland, Slovakia, Ukraine
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Biogen

Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (EXPLORE)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

United States
Ipsen

Active, not recruiting

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

Metastatic Adenocarcinoma of the Pancreas

United States, Spain, Hungary, France, Portugal, Korea, Republic of, Germany, United Kingdom, Austria, Italy, Israel, Australia, Brazil, Czechia, Belgium, Russian Federation, Canada, Greece
Actelion

Completed

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT)

Multiple Sclerosis

United States, Spain, Hungary, Israel, Portugal, Germany, Russian Federation, Belarus, Poland, Serbia, Latvia, Turkey, Croatia, Canada, Czechia, Bulgaria, Bosnia and Herzegovina, Finland, France, Georgia, Greece, Italy, Lithuania, Mexico and more
Novartis Pharmaceuticals

Recruiting

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Italy, Spain, United States, Germany, France, Serbia, Austria, Brazil, Bulgaria, Canada, Croatia, Estonia, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Sweden, Turkey, Ukraine, United Kingdom, Lithuania, Netherlands, Slovakia and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis

United States, Argentina, Poland, Canada, Australia, Belgium, Brazil, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Relapsing Multiple Sclerosis

United States, Poland, Austria, Belgium, Czechia, Germany, Australia, Switzerland, Lebanon, Argentina, Canada, Slovenia, Bulgaria, Latvia, Russian Federation, Spain, Italy, Turkey, Slovakia, Portugal, Greece, Saudi Arabia, Hungary, No... and more
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Sanofi

Completed

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Multiple Sclerosis

Finland, Belgium, Spain, Chile, Norway, Italy, United States, Austria, Canada, France, Germany, Greece, Sweden, United Kingdom
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Actelion

Completed

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russian Federation, Serbia, S... and more
Boston Scientific Corporation

Terminated

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Adenocarcinoma of the Esophagus

United States, India, Czechia, Poland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
Mallinckrodt
Mallinckrodt ARD Inc.

Completed

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

Multiple Sclerosis, Relapsing-Remitting

United States
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Genentech, Inc.

No longer available

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis

United States
Sanofi

Recruiting

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

Israel, Korea, Republic of, United States, China, Canada, Puerto Rico, United Kingdom, Chile, Turkey, Japan
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
Pfizer

Terminated

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, China, Taiwan, France, Australia, Hungary, Korea, Republic of, Germany, Japan, Switzerland, Ireland, Israel, United Kingdom, Italy, Poland, Belgium, Canada, Greece, Portugal, Austria, Russian Federation
Cabaletta Bio

Recruiting

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

MuSK Myasthenia Gravis

United States
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Amgen

Completed

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Opexa Therapeutics, Inc.

Terminated

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (OLTERMS)

Clinically Isolated Syndrome | Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
Jazz Pharmaceuticals

Terminated

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis (RELEASE MSS5)

Spasticity With Multiple Sclerosis

Spain, United States, United Kingdom, Czechia, Poland
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (GEMINI 1)

Relapsing Multiple Sclerosis

Spain, United States, Mexico, Japan, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Italy, Lithuania, Poland, Romania, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, Hong Kong
Novartis Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, United States, Belgium, Germany, Italy, Israel, Australia, France, United Kingdom, Netherlands, Czechia, Japan, Canada, Greece, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Japan, Netherlands, Poland
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Myasthenia Gravis

Italy, United States, Belgium, Canada, Netherlands, Poland, Spain, Sweden
Actelion

Terminated

Persistent Pulmonary Hypertension of the Newborn (FUTURE 4)

Persistent Pulmonary Hypertension of the Newborn

United States, Australia, Belgium, Czech Republic, France, Germany, Korea, Republic of, Poland, Russian Federation, Singapore, Switzerland, United Kingdom

Clinical Trials on Artrosis of the Knee in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations